IL210245A0 - Signatures and determinants associated with metastasis methods of use thereof yand - Google Patents

Signatures and determinants associated with metastasis methods of use thereof yand

Info

Publication number
IL210245A0
IL210245A0 IL210245A IL21024510A IL210245A0 IL 210245 A0 IL210245 A0 IL 210245A0 IL 210245 A IL210245 A IL 210245A IL 21024510 A IL21024510 A IL 21024510A IL 210245 A0 IL210245 A0 IL 210245A0
Authority
IL
Israel
Prior art keywords
yand
signatures
determinants associated
metastasis
methods
Prior art date
Application number
IL210245A
Other languages
English (en)
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of IL210245A0 publication Critical patent/IL210245A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL210245A 2008-06-26 2010-12-23 Signatures and determinants associated with metastasis methods of use thereof yand IL210245A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7593308P 2008-06-26 2008-06-26
PCT/US2009/048862 WO2009158620A2 (en) 2008-06-26 2009-06-26 Signatures and determinants associated with metastasis methods of use thereof

Publications (1)

Publication Number Publication Date
IL210245A0 true IL210245A0 (en) 2011-03-31

Family

ID=41445345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL210245A IL210245A0 (en) 2008-06-26 2010-12-23 Signatures and determinants associated with metastasis methods of use thereof yand

Country Status (14)

Country Link
US (1) US20110182881A1 (enExample)
EP (1) EP2307886A2 (enExample)
JP (1) JP2011526693A (enExample)
KR (1) KR20110036056A (enExample)
CN (1) CN102132160A (enExample)
AU (1) AU2009262022A1 (enExample)
BR (1) BRPI0914734A2 (enExample)
CA (1) CA2728674A1 (enExample)
IL (1) IL210245A0 (enExample)
MX (1) MX2010014280A (enExample)
NZ (1) NZ590385A (enExample)
RU (1) RU2011102743A (enExample)
WO (1) WO2009158620A2 (enExample)
ZA (1) ZA201100225B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20100248269A1 (en) * 2009-03-30 2010-09-30 New York Blood Center Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
CA2790284C (en) 2010-02-17 2019-01-08 Takeda Pharmaceutical Company Limited Thieno-pyrimidine compounds having cdc7 inhibitory activity
JP2013533960A (ja) 2010-06-01 2013-08-29 トドス メディカル リミテッド がんの診断
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8880457B2 (en) * 2010-11-05 2014-11-04 Allegheny-Singer Research Institute Method and system for recommending a decision based on combined entity modeling
EP2707710B1 (en) 2011-05-11 2022-08-17 Todos Medical Ltd. Diagnosis of cancer based on infrared spectroscopic analysis of dried blood plasma samples
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
JP6133297B2 (ja) * 2011-09-06 2017-05-24 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ 試料中の希少標的細胞のサイトメトリー検出のための方法及び組成物
US10322194B2 (en) 2012-08-31 2019-06-18 Sloan-Kettering Institute For Cancer Research Particles, methods and uses thereof
JP6164678B2 (ja) * 2012-10-23 2017-07-19 国立研究開発法人科学技術振興機構 ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム
EP4190918A1 (en) 2012-11-16 2023-06-07 Myriad Genetics, Inc. Gene signatures for cancer prognosis
JP6465811B2 (ja) 2012-12-19 2019-02-06 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 多様式の粒子、方法およびその使用
US20160000329A1 (en) 2013-02-20 2016-01-07 Sloan-Kettering Institute For Cancer Research Wide field raman imaging apparatus and associated methods
NZ712575A (en) * 2013-03-14 2019-08-30 Castle Biosciences Inc Methods for predicting risk of metastasis in cutaneous melanoma
US9804145B2 (en) 2013-05-28 2017-10-31 Todos Medical Ltd. Infrared analysis of benign tumors
GB201317609D0 (en) 2013-10-04 2013-11-20 Cancer Rec Tech Ltd Inhibitor compounds
US10912947B2 (en) 2014-03-04 2021-02-09 Memorial Sloan Kettering Cancer Center Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells
US20150252434A1 (en) * 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
WO2015175692A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10688202B2 (en) 2014-07-28 2020-06-23 Memorial Sloan-Kettering Cancer Center Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes
EP3259578B1 (en) * 2015-02-17 2019-10-23 Siemens Healthcare Diagnostics Inc. Model-based methods and testing apparatus for classifying an interferent in specimens
GB201505658D0 (en) 2015-04-01 2015-05-13 Cancer Rec Tech Ltd Inhibitor compounds
US10919089B2 (en) 2015-07-01 2021-02-16 Memorial Sloan Kettering Cancer Center Anisotropic particles, methods and uses thereof
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
CN109844140A (zh) * 2016-10-28 2019-06-04 茂英基因科技股份有限公司 辨识转移性肿瘤的原发位置的方法及系统
CN111094594A (zh) * 2017-07-17 2020-05-01 茂英基因科技股份有限公司 产生复数候选探针和鉴定哺乳动物中细胞类型的方法
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
JP7580210B2 (ja) * 2020-06-15 2024-11-11 三菱重工業株式会社 予兆判定装置、予兆判定方法及びプログラム
WO2023044118A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Methods for disease assessment using drain fluid
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
CN116204890B (zh) * 2023-04-28 2023-07-21 浙江鹏信信息科技股份有限公司 一种自适应增强人工智能算法安全的算法组件库
CN117171678B (zh) * 2023-11-02 2024-01-12 北京建工环境修复股份有限公司 一种微生物修复过程中土壤微生物菌群调控方法及系统

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178414A (en) * 1978-02-08 1984-11-27 Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) Packaging material having excellent seal packaging property
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4727022A (en) * 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
US5018067A (en) * 1987-01-12 1991-05-21 Iameter Incorporated Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US20020038227A1 (en) * 2000-02-25 2002-03-28 Fey Christopher T. Method for centralized health data management
US20040002071A1 (en) * 2001-09-19 2004-01-01 Intergenetics, Inc. Genetic analysis for stratification of cancer risk
US20040122296A1 (en) * 2002-12-18 2004-06-24 John Hatlestad Advanced patient management for triaging health-related data
US7468032B2 (en) * 2002-12-18 2008-12-23 Cardiac Pacemakers, Inc. Advanced patient management for identifying, displaying and assisting with correlating health-related data
US20030232398A1 (en) * 2002-03-28 2003-12-18 Macmurray James P. Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
WO2005108621A1 (en) * 2004-04-30 2005-11-17 Yale University Methods and compositions for cancer diagnosis
EP1805676A1 (en) * 2004-09-22 2007-07-11 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2007059313A1 (en) * 2005-11-16 2007-05-24 Children's Medical Center Corporation Method to assess breast cancer risk
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1996723A1 (en) * 2006-03-22 2008-12-03 Siemens Medical Solutions Diagnostics GmbH Prediction of breast cancer response to chemotherapy
PT2062049E (pt) * 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
EP2074226A2 (en) * 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
AU2007328427A1 (en) * 2006-11-06 2008-06-12 Source Precision Medicine, Inc. Gene expression profiling for identification, monitoring and treatment of melanoma
US20100233691A1 (en) * 2007-03-30 2010-09-16 Source Precision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer
US20110160072A1 (en) * 2007-10-23 2011-06-30 Clinical Genomics Pty. Ltd. Method of diagnosing neoplasms
EP2247755B1 (en) * 2008-02-14 2015-01-28 Decode Genetics EHF Susceptibility variants for lung cancer
US20110053804A1 (en) * 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
WO2009140556A2 (en) * 2008-05-15 2009-11-19 University Of Southern California Genotype and expression analysis for use in predicting outcome and therapy selection
MX337650B (es) * 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.

Also Published As

Publication number Publication date
RU2011102743A (ru) 2012-08-10
JP2011526693A (ja) 2011-10-13
CN102132160A (zh) 2011-07-20
BRPI0914734A2 (pt) 2015-10-20
US20110182881A1 (en) 2011-07-28
EP2307886A2 (en) 2011-04-13
AU2009262022A1 (en) 2009-12-30
KR20110036056A (ko) 2011-04-06
MX2010014280A (es) 2011-05-23
WO2009158620A2 (en) 2009-12-30
CA2728674A1 (en) 2009-12-30
ZA201100225B (en) 2011-10-26
NZ590385A (en) 2012-11-30
WO2009158620A3 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
ZA201100225B (en) Signatures and determinants associated with metastasis and methods of use thereof
IL269454B (en) Qualitative losses and their uses
IL210804A (en) Benzylidenehydrazides and their uses
GB2501831B (en) Paper shredder with staple and clip remover
IL241091A0 (en) Antibodies to fcrn and their use
IL209754A0 (en) Diazacarbazoles and methods of use
IL216731A (en) And antibodies against p95 – her2 and their uses
IL205977A0 (en) 5-anilinoimidazopyridines and methods of use
EP2259796A4 (en) MATERIALS AND METHODS FOR IMPROVED IMMUNE LYCOPROTEINS
IL207129A0 (en) Ron antibodies and uses thereof
EP2450582A4 (en) CLAMP AND CLAMPING DEVICE
IL206125A0 (en) Azaindolizines and methods of use
IL209548A0 (en) Diazacarbazoles and methods of use
EP2291377A4 (en) IMIDAZOPYRIMIDINONE AND ITS USES
ZA201103456B (en) Leukolectins and uses thereof
PL2247601T3 (pl) Tiazopirymidynony i ich zastosowanie
ZA201104161B (en) Dihydroetorphines and their preparation
PL2368357T3 (pl) Poprawa utrzymania bezpieczeństwa i integralności
EP2379707A4 (en) GORDONIA SIHWENSIS TRIBE AND ITS USE
GB0812277D0 (en) Antibody and uses thereof
GB0804459D0 (en) Immunotherapeutic methods and molecules
PL2167658T3 (pl) Modyfikowane liazy 13-wodoronadtlenku i ich zastosowania
GB0708208D0 (en) Markable textile and method of manufacture thereof
GB0813359D0 (en) Halfin and/or platerfin
TWI369138B (en) Speaker and application thereof